Technology
Ipsen and Biomunex Partner on First-in-Class MAIT Cell Engager for Solid Tumors in $610M Deal
Ipsen, Biomunex, MAIT cell engager, T cell engager, solid tumors, immuno-oncology, BMX-502, BiXAb technology, GPC3 tumor antigen.
Embecta Discontinues Insulin Patch Pump Program Amid Restructuring Efforts
Embecta, insulin patch pump, discontinuation, restructuring, layoffs, diabetes technology
Novo Nordisk and Ascendis Pharma Collaborate on Groundbreaking Once-Monthly GLP-1 Treatment for Obesity and Type 2 Diabetes
Novo Nordisk, Ascendis Pharma, GLP-1 receptor agonist, once-monthly treatment, obesity, type 2 diabetes, metabolic diseases, cardiovascular therapies, TransCon technology.
AbbVie Expands CNS Capabilities with $1.4 Billion Acquisition of Aliada Therapeutics
AbbVie, Aliada Therapeutics, CNS diseases, Alzheimer’s disease, anti-amyloid asset, blood-brain barrier technology, MODEL platform, ALIA-1758, pharmaceutical acquisition
Roche and Dyno Therapeutics Launch $1B+ Collaboration to Develop Next-Generation AAV Gene Therapy Vectors for Neurological Diseases
Roche, Dyno Therapeutics, AAV gene therapy vectors, Neurological diseases, AI-driven gene delivery, LEAP technology, Gene therapy collaboration
Roche Revisits Dyno for AAV Technology with $50M Upfront Payment
Roche, Dyno Therapeutics, AAV technology, gene therapy, neurological diseases, strategic partnership
Prime Medicine Partners with Bristol Myers Squibb in $3.5B Cell Therapy Deal, Narrows Pipeline Focus
Prime Medicine, Bristol Myers Squibb (BMS), Cell Therapy, Gene Editing, Prime Editing, PASSIGE Technology, Ex Vivo T-Cell Therapies, Pipeline Reprioritization, Strategic Collaboration
Novo Nordisk Partners with NanoVation in $600M Deal for Advanced Genetic Medicine Delivery
Novo Nordisk, NanoVation Therapeutics, Genetic Medicine, Lipid Nanoparticle (LNP) Technology, Cardiometabolic Diseases, Rare Genetic Disorders
Roche Secures FDA Approval for Subcutaneous Tecentriq Hybreza, Enhancing Cancer Treatment Options
Roche, FDA Approval, Tecentriq Hybreza, Subcutaneous Administration, Cancer Immunotherapy, PD-L1 Inhibitor, Halozyme Therapeutics, Enhanze Drug Delivery Technology
Highlander Health: Revolutionizing Clinical Research with Integrated Solutions
Highlander Health, clinical research, personalized healthcare, evidence generation, technology enablement, Amy Abernethy, Brad Hirsch, Verily, FDA.